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ABSTRACT
MicroRNAs (miRNAs) have been shown to play an impor-
tant role in hematopoiesis. To elucidate the role of
miRNAs in the early steps of hematopoiesis, we directly
compared donor-matched CD133
1 cells with the more dif-
ferentiated CD34
1CD133
2 and CD34
2CD133
2 cells from
bone marrow on the miRNA and mRNA level. Using quan-
titative whole genome miRNA microarray and sequencing-
based proﬁling, we found that between 109 (CD133
1)a n d
216 (CD34
2CD133
2) miRNAs were expressed. Quantiﬁca-
tion revealed that the 25 highest expressed miRNAs
accounted for 73% of the total miRNA pool. miR-142-3p
was the highest expressed miRNA with up to 2,000 copies
per cell in CD34
1CD133
2 cells. Eighteen miRNAs were sig-
niﬁcantly differentially expressed between CD133
1 and
CD34
1CD133
2 cells. We analyzed their biological role by
examining the coexpression of miRNAs and its bioinfor-
matically predicted mRNA targets and luciferase-based re-
porter assays. We provide the ﬁrst evidence for a direct
regulation of CD133 by miR-142-3p as well as tropomyosin
1 and frizzled homolog 5 by miR-29a. Overexpression of
miRNAs in CD133
1 cells demonstrated that miR-142-3p
has a negative inﬂuence on the overall colony-forming abil-
ity. In conclusion, the miRNAs expressed differentially
between the CD133
1 and CD34
1CD133
2 cells are involved
in inhibition of differentiation, prevention of apoptosis, and
cytoskeletal remodeling. These results are highly relevant
for stem cell-based therapies with CD133
1 cells and delin-
eate for the ﬁrst time how the stem cell character of
CD133
1 cells is deﬁned by the expression of speciﬁc miR-
NAs. STEM CELLS 2011;29:847–857
Disclosure of potential conﬂicts of interest is found at the end of this article.
INTRODUCTION
MicroRNAs (miRNAs) are 21–23 nucleotides long noncoding
RNAs that are negatively regulating target mRNAs on a post-
transcriptional level. Each miRNA has the potential to bind
hundreds of mRNAs and one mRNA can be targeted by mul-
tiple miRNAs [1], highlighting the importance of miRNAs in
complex networks of gene expression regulation. It is esti-
mated that >60% of the mammalian transcriptome is under
miRNA control [2]. miRNAs have been shown to play a dis-
tinct role in many different cellular, developmental, and phys-
iological processes including hematopoiesis [3].
Detailed analysis of miRNA expression in hematopoiesis
showed that miRNAs ﬁne tune essentially each step in hema-
topoiesis, as summarized in recent reviews [3, 4]. However,
most of the performed studies focused on the later steps of
hematopoietic lineage differentiation, whereas the early steps
of hematopoietic stem cell (HSC) differentiation, for example,
the role of miRNAs in self-renewal of long-term and short-
term repopulating HSCs are currently mostly unknown. Up to
now, only two studies analyzed the expression of miRNAs in
primitive human CD34
þCD38
  cells and two recent studies
in mouse lineage-negative cKit
þSca1
þ cells [5–8]. miRNA
expression proﬁles are further available for CD34
þ progenitor
cells from bone marrow and mobilized peripheral blood cells
[9] as well as CD34
þ cord blood cells [10].
CD133, also known as prominin-1, was originally found on
HSCs and hematopoietic progenitor cells (HPCs) deriving from
human fetal liver, bone marrow, peripheral blood, and
Author contributions: U.B.: designed research, performed experiments, analyzed data, and wrote the manuscript; S.W.: designed research
and interpreted data; S.T.: analyzed microarray data; M.H.: performed and analyzed sequencing experiments; H.S.: contributed
bioinformatics tools for miRNA target prediction; A.M.: performed sequencing experiments; Y.-H.C.: provided reagents; T.T.:
interpreted data; A.B.: designed research, interpreted data, and wrote the manuscript.
Correspondence: Andreas Bosio, Ph.D., Miltenyi Biotec GmbH, Friedrich-Ebert-Straße 68, 51,429 Bergisch Gladbach, Germany.
Telephone: 49-2204-8306-0; Fax 49-2204-8306-6669; e-mail: andreas.bosio@miltenyibiotec.de Received September 28, 2010; accepted
for publication February 21, 2011; ﬁrst published online in STEM CELLS EXPRESS March 10, 2011. V C AlphaMed Press 1066-5099/2009/
$30.00/0 doi: 10.1002/stem.627
STEM CELLS 2011;29:847–857 www.StemCells.comleukapheresis products from cytokine-mobilized donors [11,
12]. Further studies revealed that long-term culture-initiating
cells, the most primitive human hematopoietic cells analyzable
in vitro, are highly enriched for CD133
þ cells [13]. Moreover,
CD133
þ cells in the quiescent phase of the cell cycle have a
phenotype consistent with HSCs and have high repopulating ac-
tivity [14]. As CD34
þ cells can be generated in vitro from
CD133
þCD34
 cells [15], CD133
þ cells appear to be ancestral
to CD34
þcells. Gene expression proﬁles and repopulation
assays provided further evidence for a more primitive pheno-
type of CD133
þ cells compared with CD34
þ cells [16, 17].
In stem cell-based therapies, CD133
þ cells are used for
treatment of leukemia [18, 19], neurodegenerative diseases
[20], liver regeneration [21], and myocardial infarction [22,
23]. Currently, the intramyocardial transplantation of CD133
þ
cells is evaluated in clinical trials such as the INSTEM [24]
and PERFECT [25] trial.
To elucidate the molecular differences that account for the
more primitive character and therapeutic potential of CD133
þ
cells as compared with CD34
þ cells, we aimed at a compre-
hensive miRNA expression analysis of both subpopulations.
Recently, we described a microarray-based approach for
global and absolute quantiﬁcation of miRNAs [26]. Here, we
present the ﬁrst relative and absolute miRNA proﬁle of
CD133
þ bone marrow cells and the ﬁrst comparison of do-
nor-matched CD133
þ and CD34
þCD133
  cells on miRNA
level. The biological role of the miRNAs differentially
expressed between CD133
þ and CD34
þCD133
  cells was
further analyzed by examining the coexpression of bioinfor-
matically predicted miRNA-mRNA pairs and the inﬂuence of
miRNA overexpression in CD133
þ cells.
MATERIALS AND METHODS
Cells and Cell Sorting
HSCs were isolated from human bone marrow following written
consent from the local Ethics Committee. The mean donor age
was 79 years. CD133
þ bone marrow cells were enriched with the
CliniMACS CD133 Reagent (clone AC133, Miltenyi Biotec, Ber-
gisch Gladbach, Germany, www.miltenyibiotec.com) using the
CliniMACS Cell Separation System (Miltenyi Biotec). CD34
þ/
CD133
  cells were isolated by enrichment of CD34
þ cells with
the CliniMACS CD34 Reagent (clone QBEND/10, Miltenyi Bio-
tec) using the negative fraction of the ﬁrst separation. The gating
of the separated cells was performed according to ISHAGE.
CD133
þ cells from mobilized peripheral blood were obtained
from AllCells LLC.
RNA Sources
Total RNA was isolated from the different hematopoietic subpo-
pulations using miRNeasy Mini (Qiagen, Hilden, Germany,
www.qiagen.com). RNA quality was conﬁrmed using an RNA
6000 Pico total RNA kit (Agilent Technologies, Bo ¨blingen,
Germany, www.agilent.com). RNA integrity numbers were
between 8.2 and 9.4.
The universal reference (UR; miRXplore Universal Refer-
ence, Miltenyi), consisting of a pool of 954 miRNAs, with each
individual oligoribonucleotide having a ﬁnal concentration of
5 fmol/ll, has been described in detail [26].
RNA Processing
For miRNA proﬁling, RNA samples were complemented with
miRControl 3 and labeled using the miRCury Power Labeling Kit
(Exiqon, Vedbaek, Denmark, www.exiqon.com). Hybridization of
miRXplore microarrays was performed as described elsewhere
[26] using an automated hybridization instrument (a-Hyb Hybrid-
ization Station, Miltenyi Biotec).
For mRNA proﬁling, mRNA was ampliﬁed using the lMACS
SuperAmp Kit (Miltenyi Biotec) and hybridized on Agilent whole
genome arrays.
Microarray Design and Analysis
The miRNA microarray design of the miRXplore microarrays
(Miltenyi Biotec) has been described in detail previously [26].
The exact conﬁguration of each microarray is deposited at the
National Center for Biotechnology Information Gene Expression
Omnibus (GEO; accession number GSE22460). Analysis of the
microarrays was done as described before [26, 27].
For Agilent whole genome arrays, scanned images were ana-
lyzed using the Agilent Feature Extraction software (Version 9.1)
by which the local background was subtracted. A two-tailed t test
was used to determine the signal versus background signiﬁcance.
The signiﬁcance values were used for ﬁltering of the data set,
considering only those signals with p < .01 on at least three of
eight arrays (CD133 and CD34 samples) or two of four arrays
(Neg samples). After that, the signal intensity data was normal-
ized to the array median and multiplied by the median calculated
from all values.
For downstream statistical analysis of miRNA and mRNA
array data, ratios were log 2 transformed and data imported into
the MeV program, which is part of the TM4 package [28]. Two-
dimensional hierarchical clustering was done using Euclidean dis-
tance. The statistical analysis of microarrays was performed using
signiﬁcance analysis of microarrays (SAM) with at least 100 per-
mutations per analysis, t test with p < .05 and adjusted Bonfer-
roni correction or t test with p < .01.
Quantitative Real-Time Polymerase Chain
Reaction and miRNA Cloning
The miScript PCR System (Qiagen) was used to validate miR-
NAs detected as differentially expressed on microarrays. The
real-time polymerase chain reaction (RT-PCR) reaction and the
real-time PCR were carried out according to the manufacturer’s
protocol. Data were normalized using RNU6B (MS00014000) or
RN5S1(MS00007574). PCR reactions were performed in tripli-
cates and carried out in an ABI Prism 7000 SDS Real Time PCR
machine (Applied Biosystems, Foster City, CA, www.appliedbio
systems.com) and analyzed using ABI Prism 7000 System SDS
software (version 1.1).
Small RNA cDNA library preparation procedure was per-
formed with 2 lg total RNA as input following the basic protocol
described in Hafner et al. [29].
miRNA Target Prediction
Prediction of miRNA targets was performed using TargetScan
[30], miRDB [31], PicTar [32], ElMMo [33], miRanda [34], and
PITA [35]. For further analysis, targets either predicted by at
least three of six target prediction tools or targets predicted exclu-
sively by TargetScan were used.
Combined analysis of miRNA and mRNA proﬁles was car-
ried out by investigating the coexpression of the bioinformatically
predicted miRNA-mRNA pairs. The predicted targets were
selected based on [1] their expression level and/or [2] based on
inversed expression, for example, miRNA upregulated and the
predicted mRNA downregulated.
The expressed (detected) signals were ﬁltered as follows:
probes with a p below .01 on 75% of the arrays were considered,
excluding probes being present in the lowest quartile of the array
or if it was not detected on more than 75% of the arrays.
The predicted and coexpressed mRNAs were tested for a sig-
niﬁcant enrichment of annotations using the proprietary TreeR-
anker software (Miltenyi Biotec). As annotation sources, data-
bases containing information on gene ontology (GO) categories,
protein sequence motifs, interaction data, complex membership,
and involvement in biological pathways were used. As
848 miRNAs in CD133
þ Cellsbackground for the analysis, the probe set of the ﬁltered Agilent
Whole Human Genome Oligo Microarray was chosen. Enrich-
ment p values were computed by Fisher’s exact test with subse-
quent correction for multiple testing using Benjamini Hochberg
FDR. The Enrichment Factor is a parameter that shows the extent
to which genes in an annotation group are overrepresented, for
example, if A of B analyzed genes are annotated as ‘‘category X’’
and overall C of D genes on the whole microarray are annotated
as ‘‘category X’’, the enrichment factor is (A/B)/(C/D). The p
value threshold was .05 and the factor of enrichment was required
to be at least 3.
Luciferase Assays
60mer DNA oligonucleotides (Metabion, Martinsried, Germany,
www.metabion.com) consisting of the test sequence (FZD5:
AAACTACATATGGCCAAGGTCACTTCCG TTTACCTTCAT
GGTGCTGTTGCCCCCTCCCC; tropomyosin 1 (TPM1): AAAC
TACATATGTGTTGGAAACACAATCAGGTGTGGATTGGTGC
TACTTTGAACAAAAC; CD133: AAACTAGCGGCCGCACTT
TTTTACACTGAGT TTCTATTTAGACACTACAACATATGGG
GTGC) ﬂanked by PmeI, XhoI (overhangs), and NdeI or NotI (in-
ternal) restriction sites were cloned downstream of the ﬁreﬂy lucif-
erase gene into the pmirGLO dual-luciferase miRNA Target
Expression Vector (Promega, Madison, WI, www.promega.com)
using standard procedures.
HEK293T cells were plated into 96-well plates and cotrans-
fected with the described luciferase reporter construct and the
appropriate miRNA precursor (Applied Biosystems) using Attrac-
tene (Qiagen). Lumincescence was quantitated 48 hours after
transfection by using the Dual Glo Luciferase Assay System
(Promega) on a GENios Reader (Tecan, Ma ¨nnedorf, Switzerland,
www.tecan.com).
Cell Division Tracking and Colony-Forming
Unit Assays
CD133þ cells were cultivated in StemSpan serum-free medium
(StemCell Technologies, Vancouver, Canada, www.stemcell.com)
supplemented with 10 lg/ml heparin (Ratiopharm, Ulm, Germany,
www1.ratiopharm.com), 10 ng/ml mouse SCF (R&D Systems), 20
ng/ml mouse TPO (R&D Systems, Minneapolis, MN, www.rndsys-
tems.com), and 10 ng/ml human FGF-1 (Invitrogen, Frederick,
MD, www.invitrogen.com). Cells were cultured at 37 Ci n5 %C O 2
in U-bottom 96-well plates with 150 ll of the indicated medium.
The number of cell divisions were analyzed using carboxyﬂuores-
cein diacetate N-succinimidyl ester (CFSE; Sigma-Aldrich, Stein-
heim, Germany, www.sigmaaldrich.com) labeling as described by
Walenda et al. [36]. One day after CFSE labeling the CD133þ cells
were transfected with appropriate miRNA precursor (Applied Bio-
systems). Transfection was performed by using HiPerfect (Qiagen)
according to the manufacturer’s protocol.
For colony-forming unit (CFU) assays, transfected cells added
to methylcellulose media (HSC-CFU complete with Epo; Milte-
nyi) and plated in 6-well plates at a ﬁnal concentration of 150
CD34
þcells per milliliter. After incubation for 14 days at 37 C
and 5% CO2 colonies were classiﬁed by their color and morphol-
ogy using an inverted microscope.
RESULTS
Relative and Absolute miRNA Expression in
CD133
1 Cells
CD133
þ cells were magnetically isolated from bone marrow
by MACS technology. Subsequently, CD34
þCD133
  cells
were isolated using the negative fraction of the ﬁrst separation
(Fig. 1A). Besides the CD34
þCD133
  cell population,
CD34
 CD133
  cells (the negative fraction of the second sep-
aration) were also analyzed and compared with CD133
þ cells
to get a general impression of miRNA expression in bone
marrow cells. As the main cell type present in the
CD34
 CD133
  fraction are erythrocytes, an additional analy-
sis of CD34
 CD133
  cells after red blood cell (RBC) lysis
was performed (Neg  R). Here, the main cell population is
neutrophilic granulocytes [37].
RNA samples from the bone marrow subpopulations, that
is, CD133
þ, CD34
þCD133
 , CD133
 CD34
  (Neg þR), and
CD133
 CD34
  (Neg  R), of ﬁve different donors and addi-
tionally two samples of CD133
þ cells from mobilized leuka-
pheresis (Supporting Information Table 1) were labeled with
Cy5 and hybridized versus the Cy3-labeled miRXplore Uni-
versal Reference. The UR is an equimolar pool of 954 syn-
thetic miRNAs of known concentration that allows direct
comparison of miRNA expression across multiple experiments
and absolute quantiﬁcation [26].
The overall number of detected miRNAs (in at least four
of ﬁve donors) was 109 in CD133
þ cells, compared with 126
miRNAs in CD34
þCD133
  cells (Supporting Information
Fig. 1), 151 miRNAs in CD133
 CD34
  cells without RBCs
(Neg –R), and 216 miRNAs in CD133
 CD34
  cells with
RBCs (Neg þR). The diversity of miRNAs was highest in the
CD133
 CD34
  cell population including RBCs and lowest in
CD133
þ and CD34
þCD133
  cells.
Next, we performed a cluster analysis of the miRNAs
expressed in CD133
þ and CD34
þCD133
  cells. The four sub-
populations clustered separately as visualized in Figure 2 and
revealed distinct miRNA signatures for the different cell pop-
ulations. As expected, the similarity between CD133
þ and
CD34
þCD133
  cells was higher than between CD133
þ and
CD34
 CD133
  cells which mainly consist of granulocytes
(Neg  R) or RBCs (Neg þR).
The miRNA proﬁles of the CD133
þ bone marrow samples
and the CD133
þ mobilized leukapheresis samples were highly
similar with the notable exception of miR-451 and miR-144
expression that could only be detected in the samples derived
from bone marrow and not in the leukapheresis samples.
SAM was performed to investigate the differences
between CD133
þ and CD34
þCD133
  cells (Fig. 3A). Eight-
een miRNAs were signiﬁcantly differentially expressed (false
discovery rate [median] < 0.0001%) with three distinct expres-
sion signatures: 13 miRNAs (group 1 and 2) were signiﬁcantly
higher expressed in CD133
þ compared with CD34
þCD133
 
cells. These 13 miRNAs could be divided into one group of
miRNAs that were not expressed in CD34
 CD133
  cells
(group1) and another group where the expression in
CD34
 CD133
  cells was even higher than in CD133
þ cells
(group 2). Five miRNAs (group 3) were signiﬁcantly lower
expressed in CD133
þ cells as in CD34
þCD133
  cells.
These three expression signatures were observed with
both populations of CD34
 CD133
  cells. The miRNAs in
group 1 seemed to be most speciﬁc for HSCs and HPCs as
they were not expressed in the bulk of bone marrow cells.
The ratios for the 18 miRNAs signiﬁcantly differentially
expressed between CD133
þ and CD34
þCD133
  cells are
shown in Supporting Information Table 2.
The microarray data was also used to calculate the
miRNA copy numbers per cell for the hematopoietic cell pop-
ulations of four different donors. This absolute quantiﬁcation
was possible as the samples were hybridized versus the UR
and analyzed according to our previously published method
for absolute quantiﬁcation [26]. The miRNA copy numbers
were calculated for all detected miRNAs being also present in
the UR and Spearman correlation coefﬁcients were deter-
mined to assess the overall performance and to show the rela-
tionship between the different samples. The Spearman
Bissels, Wild, Tomiuk et al. 849
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sion proﬁles were 0.88–0.97 for the CD133
þ cells and 0.90–
0.95 for the CD34
þCD133
  cells. A comparison of the
CD133
þ cells with the CD34
þCD133
  cells led to correlation
coefﬁcients between 0.81 and 0.94 (Supporting Information
Table 3). Taken together, the correlation coefﬁcients revealed
a high similarity between different donors and a robust abso-
lute measurement of miRNAs.
Next, the miRNA copy numbers were analyzed in detail.
The majority of all detected miRNAs, 79% in CD133
þ cells
and 73% in CD34
þCD133
  cells, were present with less than
200 copies per cell, whereas the highest expressed miRNAs
showed copy number of around 2,000 per cell (Fig. 3B). The
most abundant miRNAs in CD133
þ cells were miR-26a
(7.2% of overall copy numbers), miR-451 (7.0%), and miR-
26b (6.5%). The 25 highest expressed miRNAs in CD133
þ
Figure 1. Experimental proce-
dure for miRNA expression
analysis in hematopoietic stem
cells and hematopoietic progeni-
tor cells. (A): After separation
of CD133
þ, CD34
þCD133
 ,
and CD34
 CD133
  cells, the
RNA was isolated and further
processed for miRNA or mRNA
proﬁling. Hybridization was car-
ried out using miRXplore micro-
arrays for miRNA analysis and
Agilent Whole Human Genome
Oligo Microarrays for mRNA
analysis. Subsequently, the
miRNA and mRNA proﬁles were
used to elucidate the biological
function of the signiﬁcantly dif-
ferentially expressed miRNAs.
(B): Detailed workﬂow for the
combined miRNA and mRNA
analysis. Abbreviations: miRNA,
microRNAS.
850 miRNAs in CD133
þ Cellsand CD34
þCD133
  cells accounted for 72.8% and 74.2%,
respectively, of the overall miRNA pool (Supporting Informa-
tion Table 4). However, these miRNAs are neither exclusively
found in CD133
þ and CD34
þCD133
  cells nor are most of
them differentially expressed between the two populations.
The signiﬁcantly differentially expressed miRNAs (Fig.
3A) showed rather low expression levels with copy numbers
below 200 copies per cell with exception of miR-142-3p with
up to 5,000 copies per cell for one donor. Figure 3C displays
the copy numbers of three exemplary miRNAs representing
the three different expression signatures of the differentially
expressed miRNAs in CD133
þ cells. miR-10a was expressed
at highest level in CD133
þ cells (group 1), miR-29a at high
level in CD133
þ and CD34
 CD133
  cells (group 2), and
miR-425 at lowest level in CD133
þ cells (group 3).
Validation of miRNA Microarray Data
We validated our miRNA microarray results using hybridiza-
tion-independent methods, small RNA cDNA library sequenc-
ing and quantitative (q) RT-PCR.
Small RNA cDNA libraries were generated from 2 lgo f
total RNA of CD133
þ and CD34
þCD133
  cells from donor 7
and 10 and Solexa sequenced. To allow for the quantiﬁcation
of the total miRNA levels, 5 fmol of a cocktail of synthetic
calibrator sequences without a match to the human genome
were spiked into the samples. For each of the small RNA,
cDNA libraries between 210,000 and 300,000 sequence reads
were obtained and of these about 67% were annotated as
miRNAs. We focused on the robustly expressed ones and con-
sidered only miRNAs showing a minimum of 100 sequence
reads.
Ninety-ﬁve miRNAs were sequenced with over 100
counts compared with 135 miRNAs detected onefold over
background on all arrays. The overlap between the two groups
was 81 miRNAs detected with both methods (Fig. 4A).
Comparison of sequencing and microarray hybridization
for the miRNAs detected with both methods led to Spearman
correlation coefﬁcients of 0.74 (CD34
þCD133
  cells of donor
7), 0.73 (CD34
þCD133
  cells of donor 10), 0.82 (CD133
þ
cells of donor 7), 0.71 (CD133
þ cells of donor 10), and at
least 0.94 within each method.
The relative frequencies of miRNA sequence read
numbers of the 18 miRNAs detected as signiﬁcantly differ-
entially expressed between CD133
þ and CD34
þCD133
 
samples (Fig. 3A) very well reﬂect the microarray results
(Fig. 4B). Twelve of thirteen higher expressed and four of
ﬁve lower expressed miRNAs were validated for donor
7, for donor 10 all higher expressed miRNAs and two of the
lower expressed miRNAs were validated. Sequencing data
revealed six further miRNAs that were expressed higher in
CD133
þ cells as compared with CD34
þCD133
  cells,
namely, miR-99b, miR-144*, let-7c, miR-181d, miR-22, and
miR-222. Additionally, miR-128 was found to be lower
expressed in CD133
þ cells.
As a further control, qRT-PCR was performed for six arbi-
trary selected miRNAs (Fig. 4C). The results correlated well
with the microarray and the sequencing-based approaches.
Combined miRNA and mRNA Analysis
To further analyze the role of the differentially expressed
miRNAs in CD133
þ stem cells, we generated mRNA micro-
array expression proﬁles (Supporting Information Table 5 and
Supporting Information Fig. 2) and examined the coexpres-
sion of bioinformatically predicted miRNA-mRNA pairs. Two
main approaches for the combined miRNA and mRNA analy-
sis were used (Fig. 1B). The ﬁrst one focused on potential tar-
get mRNAs that were expressed in the same cell population
Figure 2. Average linkage cluster of miRNAs expressed in CD133
þ,
CD34
þCD133
 ,a n dC D 3 4
 CD133
  (Neg) cells. The cluster was
obtained from array hybridizations of different bone marrow subpopula-
tions (n ¼ 5) and leukapheresis samples (mPB, n ¼ 2) versus universal
reference. Those miRNAs were included where the net signal intensity
of the sample miRNA was onefold over background in at least four of
ﬁve donors in the CD133
þ and/or CD34
þCD133
  cell population and
where the miRNA was present in the UR. Neg þR: CD34
 CD133
 
with RBCs; Neg  R: CD34
 CD133
  after RBC lysis. Log 2-trans-
formed expression ratios are indicated from  3.0 (green) to 3.0 (red).
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where the effect of a miRNA on the mRNA level of its target
is quite modest and therefore, not measurable are also consid-
ered. In contrast, the second approach focused on inversely
expressed miRNAs and mRNAs.
For the ﬁrst analysis, target prediction was carried out for
each of the groups in Figure 3A separately considering targets
that were predicted by at least three target prediction tools.
Subsequently, the mRNA expression proﬁles were used to
select the expressed mRNAs among the predicted mRNAs
followed by an annotation enrichment analysis. For the seven
miRNAs (miR-146b-5p, miR-125a-5p, miR-125b, miR-99a,
miR-146a, miR-10a, miR-551b) higher expressed in CD133
þ
cells compared with CD34
þCD133
  cells and CD34
 CD133
 
cells (Supporting Information Tables 6 and 7) annotation
groups such as insulin signaling, B-cell receptor signaling,
and positive regulation of cell differentiation were enriched.
Most interestingly, the predicted targets for the miRNAs
higher expressed in CD133
þ cells were also enriched for the
GO category ‘‘hematopoietic or lymphoid organ develop-
ment’’ which comprises transcription factors such as ETS1,
KLF11, and HOXB3.
The targets predicted for the second group of higher
expressed miRNAs in CD133
þ cells (miR-29a, miR-29b, miR-
29c, miR-23a, miR-23b, miR-24) were enriched for annotations
related to developmental processes, the plasma membrane-
Figure 3. Relative and absolute expression of miRNAs in CD133
þ cells. (A): Cluster analysis of miRNAs identiﬁed by discriminatory gene
analysis of CD133
þ cells compared with CD34
þCD133
  cells. Discriminatory gene analysis was done by using the signiﬁcance analysis of
microarrays algorithm returning 18 miRNAs (false discovery rate (median): < 0.0001%) differentially expressed between CD133
þ and
CD34
þCD133
  cells. The resulting miRNAs were grouped by similarities in expression patterns using two-dimensional hierarchical average link-
age clustering. (B): Histogram displaying the number of miRNAs in distinct copy number intervals, for example, 87 of the miRNAs detected in
CD133
þ cells were present with less than 200 copy numbers per cell and 10 miRNAs with copy numbers between 201 and 400. (C): MicroRNA
copy numbers prepared from four different donors (donor no. 7, 8, 10, and 11). The three miRNAs represent the three different expression signa-
tures of the differentially expressed miRNAs: miR-10a (group1), miR-29a (group 2), and miR-425 (group 3). Neg: CD34
 CD133
  cell subpopu-
lation after red blood cell lysis (Neg  R).
852 miRNAs in CD133
þ Cellsbound protein complex SNARE and negative regulation of cell
migration (Supporting Information Tables 6 and 7).
The targets for the lower expressed miRNAs, that is, miR-
142-3p, miR-142-5p, miR-484, miR-425, and miR-191, in
CD133
þ cells showed a high enrichment for the ubiquitin pro-
teasome system (UPS) (Supporting Information Tables 6 and 7).
In conclusion, the annotation analysis indicated that the sig-
niﬁcantly differentially expressed miRNAs in CD133
þ cells play
a role in maintaining the stem cell character: The higher
expressed miRNAs target mRNAs involved in cell differentiation
and may prevent differentiation, whereas the lower expressed
miRNAs target relevant mRNAs for the UPS that is known to be
involved in the ﬁne-tuning of HSC homeostasis [38].
In a second approach (Fig. 1B), we analyzed inversely
expressed miRNAs and mRNAs and found 46 mRNAs that
were lower expressed in CD133
þ cells and targets of the 13
higher expressed miRNAs in CD133
þ cells (Supporting Infor-
mation Table 8). A functional grouping analysis for the 46
predicted and lower expressed mRNAs revealed a signiﬁcant
enrichment of biological processes related to development,
cellular import/export, cell differentiation, cytoskeleton, and
cell migration (Supporting Information Fig. 3). An interesting
example for the 46 predicted and lower expressed targets was
FZD5, a receptor of the Wnt-signaling pathway, and TPM1,
an actin binding protein, both predicted targets of miR-29a.
For the lower expressed miRNAs and higher expressed
mRNAs in CD133
þ cells just eight miRNA-mRNA pairs were
found (Supporting Information Table 9). Interestingly, the
miRNA-mRNA pair miR-142-3p and CD133 was one of the
predictions suggesting that a low miR-142-3p expression might
allow higher expression of CD133 in CD133
þ progenitor cells.
In Vitro Characterization of Functional miRNA and
mRNA Interactions
Luciferase reporter-based assays were used to analyze some
of the miRNA-mRNA interactions. In detail, we cloned the
respective miRNA-binding site region of the FZD5, TPM1,
and CD133 30UTRs behind a luciferase reporter gene (Fig. 5
and Supporting Information Fig. 4). Direct interactions of
miRNAs and putative target sites are then assessed based on
selective degradation or translational repression of luciferase
target gene 30UTR fusion transcripts.
Cotransfection of 100 nM miR-29a and 300 ng pMIR-
Luc-FZD5 decreased the luciferase activity by 40% and an
even higher decrease of 60% was achieved by decreasing the
vector amounts (Supporting Information Fig. 4). Besides miR-
29a, binding sites for miR-24 and miR-99a were predicted
within the FZD5 30UTR. We also tested their potential func-
tion, but a reproducible decrease in luciferase activity was not
detectable for either of the tested miRNAs (data not shown).
Figure 4. Validation of microarray data via Solexa sequencing and
quantitative real-time polymerase chain reaction (qRT-PCR). (A):
Venn diagram showing miRNAs detected with over 100 counts
(sequencing) or onefold over background (array data) in CD133
þ
and/or CD34
þCD133
  cells. (B): The ratios of CD133
þ counts versus
CD34
þCD133
  counts for the 18 signiﬁcantly differentially expressed
miRNA are displayed for two donors. miRNAs that were present with
less than 100 counts are marked with ‡. (C): The expression levels of
six miRNAs were also determined by qRT-PCR using the miScript
system for two (miR-125b, miR-551b) or three donors. RN5S1 was
used for normalization.
Figure 5. Veriﬁcation of miRNA-mRNA interactions via luciferase
assay. Cotransfection of pMIR-Luc-FZD5 and 100 nM miR-29a
decreased 41% of the luciferase activity in comparison with the blank
control. Cotransfection of pMIR-Luc-TPM and miR-29a decreased
the luciferase activity by 33% and pMIR-Luc-CD133 and miR-142-3p
by 30%. For each cotransfection, 300 ng vector and 50 nM (miR-
142-3p) or 100 nM (miR-29a) oligonucleotide were used. Relative lu-
ciferase activity represents ﬁreﬂy luciferase activity normalized versus
renilla activity. Data are representative of at least ﬁve independent
experiments. miR-Neg, oligonucleotide designed to serve as negative
control.
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upon cotransfection with miR-29a and again an even higher
decrease of 58% was observed using lower vector amounts.
The negative control using pMIR-Luc without cloned target
sequence showed no decrease in luciferase activity after
cotransfection with miR-29a.
The inﬂuence of miR-142-3p, that was described as hema-
topoietic speciﬁc [27], on pMIR-Luc-CD133 was less pro-
nounced, the luciferase activity was decreased by 20%–30%.
Interestingly, this effect was achieved reproducibly just with
50 nM miR-142-3p mimic and not with 100 nM miR-142-3p.
In conclusion, the luciferase assays indicated that FZD5, a
receptor of the Wnt-signaling pathway, and TPM1, which are
lower expressed in CD133
þ cells, are controlled by miR-29a.
The expression of CD133 is probably regulated by the hema-
topoietic-speciﬁc miRNA miR-142-3p.
Inﬂuence of miR-142-3p and miR-425 on
Proliferation and Differentiation of CD133
1 Cells
The inﬂuence of miR-142-3p and miR-425 on CD133
þ cells
was analyzed by performing the CFSE staining method and
CFU assays.
CD133
þ cells were stained with CFSE and transfected
with miR-142-3p, miR-425, or a control miRNA (miR-Neg)
and cultivated for 6 days. The ﬂuorescence dye CFSE is pre-
cisely halved at each cell generation, and therefore, prolifera-
tion is associated with reduced CFSE signal intensity. miR-
142-3p as well as miR-425 led to a slightly but signiﬁcantly
decreased proliferation of CD133
þ cells (p < .01 and p <
.02, respectively, see Supporting Information Fig. 5). Notably,
CD133
þ cells transfected with miR-142-3p showed a decrease
in the overall colony-forming ability of 71% (Fig. 6), whereas
miR-425 decreased the percentage of CFU-M from 20% to
8.5% (Supporting Information Fig. 6).
DISCUSSION
The miRNA signature comprising relative and absolute
expression levels of CD133
þ cells was determined by micro-
arrays, qRT-PCR, and Solexa sequencing. On this basis, we
selected differentially expressed miRNAs in CD133
þ cells in
comparison with CD34
þCD133
  cells.
CD133 appear to be ancestral to CD34, as CD34
þ cells
can be generated in vitro from CD133
þCD34
 cells [15]. To
elucidate the molecular architecture of CD133
þ cells and the
role of miRNAs in the early steps of hematopoiesis, we com-
pared CD133
þ cells with CD34
þCD133
  cells. It is notewor-
thy that most of the CD133
þ cells (>99%) express CD34 and
half of the CD34
þ cells express CD133 [13].
Currently, the available miRNA proﬁles for human HSCs
and HPCs are restricted to CD34
þ cells from bone marrow,
peripheral blood, mobilized peripheral blood and cord blood
[9, 10, 27], CD34
þCD38
  cells from cord blood [5, 6], and
CD133
þ cells from mobilized peripheral blood [39]. To our
knowledge, here, we compared for the ﬁrst time CD133
þ and
CD34
þCD133
  bone marrow cells from the same donor on
miRNA and mRNA level. Most of the miRNAs (79%) in
CD133
þ cells were present with less than 200 copies per cell
and the 25 highest expressed miRNAs accounted for 72.8%
of the miRNA pool. A ﬁnding that correlates well with previ-
ously published sequencing data [40]. The majority of
miRNAs was expressed at low levels, whereas only a few
miRNAs were expressed at high level with around 2,000 cop-
ies per cell (Fig. 3B), for example, miR-26a amounted to
7.2% of the overall miRNA pool. Although miR-26a was
expressed at high levels, it is possible that the majority of
low-expressed miRNAs are of biological signiﬁcance when
acting in combination with other low-expressed miRNAs [41].
A combined miRNA and mRNA analysis was performed
to develop a model for the biological role of the 18 differen-
tially expressed miRNAs in CD133
þ stem cells (Fig. 3A).
The mRNA data used for ﬁltering of the predicted targets was
generated from the same cells as the miRNA proﬁles.
Notably, mRNAs expressed in CD133
þ cells and pre-
dicted to be targeted by miRNAs higher expressed in
CD133
þ cells as compared with CD34
þCD133
  and
CD34
 CD133
  cells (group 1; Fig. 3A) were enriched for the
GO category ‘‘hematopoietic or lymphoid organ develop-
ment.’’ Interestingly, the corresponding miRNAs have already
been described to play a role in hematopoiesis. It was shown
that miR-10a [42], miR-146a [43], and miR-125b [44] inhibit
differentiation of speciﬁc hematopoietic lineages (Fig. 7A).
Furthermore, p53 and the proapoptotic B-cell CLL/lym-
phoma 2 antagonist killer 1 (BAK1) are targeted by miR-125b,
suppressing apoptosis in human cancer cells [45, 46]. BAK1 is
also directly downregulated by miR-125a [47]. In addition, sup-
pression of v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2 (ERBB2) and ERBB3 by enforced expression of
miR-125a or miR-125b resulted in impaired anchorage-depend-
ent growth in breast cancer cells [48]. As activation of ERBB2
can induce loss of cell polarity, suppression of ERBB2 by
miR-125 in CD133
þ cells might lead to a more polarized
morphology.
Taken together, miR-146, miR-10a, and miR-125b might
prevent differentiation, whereas miR-125b seems to play an
antiapoptotic role in CD133
þ cells as well as taking part in
remodeling of the cytoskeleton (Fig. 7A).
The second group of higher expressed miRNAs in
CD133
þ cells compared with CD34
þCD133
  cells were also
highly expressed in CD34
 CD133
  cells (group 2; Fig. 3A)
and were among others enriched for annotations related to de-
velopmental processes, negative regulation of cell migration
and collagens. Roles for the respective miRNAs in develop-
mental processes were already shown for miR-23a, miR-23b,
miR-29a, and miR-24 [49–51]. Furthermore, an inﬂuence of
miR-29b on the regulation of the extracellular matrix and of
Figure 6. miR-142-3p inhibits colony formation by CD133
þ cells.
CD133
þ cells were transfected with 50 nM miR-142-3p or control
(miR-Neg) and cultivated for 7 days. After 7 days of cultivation, the
progeny (150 CD34
þ cells per 1 ml) was seeded in methylcellulose
medium. The overall colony-forming ability was decreased by 71%
(n ¼ 4). Abbreviations: CFU, colony-forming unit; HPC, hematopoi-
etic progenitor cell.
854 miRNAs in CD133
þ CellsmiR-24a on the proapoptotic factor caspase 9 was demon-
strated [52, 53].
The predicted targets of the lower expressed miRNAs
(group 3; Fig. 3A) were highly enriched for the UPS and the
regulation of cytoskeleton organization. Interestingly, a function
of miR-142-5p in ubiquitin-mediated proteolysis and of miR-
142-3p in regulation of cytoskeleton was also predicted by
Tsang et al. [54] using the computational method mirBridge.
After analyzing the coexpression of bioinformatically pre-
dicted miRNA-mRNA pairs (approach I; Fig. 1B), we focused
Figure 7. Model for the biological role of signiﬁcantly differentially expressed miRNAs in CD133
þ cells. (A): The targets of the miRNAs are
highly relevant in the context of differentiation (green), apoptosis (blue), and cytoskeletal remodeling (red). Predicted miRNA-mRNA interactions
are shown as dashed line. Targets that were validated in our laboratory are encircled (Fig. 5). The references for the other validated miRNA-
mRNA interactions are mentioned in the text. (B): Hypothesis for the biological role of miRNAs in CD133
þ cells. Abbreviations: BAK1, Bcl-2
antagonist killer 1; CASP9, caspase 9; FZD5, frizzled homolog 5; IRAK1, interleukin-1 receptor–associated kinase 1; NF-jB, nuclear factor of j
light polypeptide gene enhancer in B-cells 1; TRAF 6, TNF receptor–associated factor 6; UPS, ubiquitin proteasome system.
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Fig. 1B) and analyzed some of them via luciferase assays.
One of those pairs was miR-29a and TPM1, an important
component of the cytoskeleton playing a fundamental role in
many aspects of eukaryotic cell behavior such as cell mor-
phology, divisions, and motility. Our results revealed that
TPM1 can be regulated by miR-29a and that this interaction
could lead to a lower expression of TPM1 in CD133
þ cells.
As tropomyosin inhibits lamellipodium formation [55], a
l o w e re x p r e s s i o no fT P M 1i nC D 1 3 3
þ cells might lead to
enhanced podia formation as compared with CD34
þCD133
 
cells. Interestingly, it was described that more primitive
HPCs possess more lamellipodia with strong expression of
CD133 [56].
Another inversely correlated miRNA-mRNA interaction
was miR-29a and FZD5, one of the seven-pass transmem-
brane Frizzled receptors, which bind Wnt proteins. Wnt sig-
naling controls diverse processes such as cell proliferation
and stem cell maintenance. A role for Wnt signaling in self-
renewal of HSCs was demonstrated by Reya et al. [57]. Regu-
lation of cell polarity and migration by ß-catenin-independent
Wnt pathways was also described [58].
Another very interesting interaction that was validated via
luciferase assay was the binding of miR-142-3p, being lower
expressed in CD133
þ cells than in CD34
þCD133
  cells, to the
CD133 mRNA. Our results also provided ﬁrst evidence that
miR-142-3p has a negative inﬂuence on the proliferation of
CD133
þ cells. However, further analysis is necessary to show
if the surface expression of CD133 is controlled by miRNAs.
According to the biological effects of the miRNAs summar-
ized above (Fig. 7A), the miRNAs higher expressed in CD133
þ
cells prevent differentiation, are antiapoptotic and regulate the
cytoskeleton leading to enhanced podia formation and cell polar-
ity (Fig. 7B). The miRNAs higher expressed in CD34
þCD133
 
cells repress the ubiquitin-proteasome system and negatively
inﬂuence the proliferation of CD133
þ cells. Taken together, it is
proposed that the miRNAs signiﬁcantly differentially expressed
in CD133
þ cells as compared with CD34
þCD133
  function by
ﬁne-tuning the expression of their targets to a precise level at
which the gene will execute its speciﬁc function to prevent proc-
esses such as differentiation and apoptosis. In addition, they
play a role in remodeling of the cytoskeleton. Detailed func-
tional analysis of miRNA effects in CD133
þ cells will gain fur-
ther insights into the role of miRNAs in stem cells.
CONCLUSION
We have presented the ﬁrst relative and absolute miRNA pro-
ﬁle of CD133
þ bone marrow cells and the ﬁrst comparison of
donor-matched CD133
þ and CD34
þCD133
  cells on miRNA
level. Our results have provided evidence that the miRNAs dif-
ferentially expressed between the CD133
þ and CD34
þCD133
 
cells are involved in inhibition of differentiation, proliferation,
prevention of apoptosis, and cytoskeletal remodeling.
These ﬁndings extend our knowledge about the molecular
architecture of CD133
þ cells that are used in regenerative
medicine as stem cell-based therapy for tissue regeneration.
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